human NET

By Targets:	5-HT Receptor (3) Adrenergic Receptor (4) Akt (4) Bacterial (1) Bradykinin Receptor (1) Calcium Channel (1) Dopamine Receptor (1) Dopamine Transporter (2) Histamine Receptor (1) iGluR (1) Interleukin Related (1) Isotope-Labeled Compounds (5) mAChR (1) MDM-2/p53 (1) Monoamine Transporter (3) mTOR (4) NF-κB (1) P-glycoprotein (4) PI3K (4) Prostaglandin Receptor (2) Serotonin Transporter (9) Small Interfering RNA (siRNA) (1) Sodium Channel (2) Trk Receptor (5)
By Research Areas:	Cardiovascular Disease (2) Endocrinology (4) Infection (1) Inflammation/Immunology (6) Neurological Disease (15)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99444

Astegolimab 2 Publications Verification MSTT 1041A; RG 6149	Interleukin Related MDM-2/p53 NF-κB	Cardiovascular Disease Inflammation/Immunology
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .

HY-19907

Liafensine BMS-820836	Dopamine Transporter Monoamine Transporter Serotonin Transporter	Neurological Disease
Liafensine (BMS-820836) is an orally active, blood-brain barrier-permeable monoamine reuptake inhibitor, with an IC₅₀ of 5.67 nM against DAT, 1.08 nM against SERT, and 7.99 nM against NET. Liafensine binds to DAT to block dopamine reuptake. Liafensine binds to SERT to block serotonin reuptake. Liafensine binds to NET to block norepinephrine reuptake. Liafensine can be used in studies related to depression .

HY-B0168B

Levomilnacipran hydrochloride 1 Publications Verification (1S,2R)-Milnacipran hydrochloride; F-2695 hydrochloride	Serotonin Transporter Trk Receptor PI3K Akt mTOR P-glycoprotein	Neurological Disease Inflammation/Immunology
Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .

HY-133116

4-Hydroxyatomoxetine	Adrenergic Receptor	Neurological Disease
4-Hydroxyatomoxetine is an active metabolite of Atomoxetine. 4-Hydroxyatomoxetine is metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-135096

Amitriptyline-d3 hydrochloride	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease
Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride). Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity .

HY-148866

Cavα2δ1&NET-IN-3	Calcium Channel	Neurological Disease Endocrinology
Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has K_is of 100-500 nM for human α2δ-1 subunit of Ca_v2.2 calcium channel and NET, respectively .

HY-14794A

Levomilnacipran (1S,2R)-Milnacipran; F2695	Serotonin Transporter Trk Receptor PI3K mTOR P-glycoprotein Akt	Neurological Disease Inflammation/Immunology
Levomilnacipran ((1S,2R)-Milnacipran) is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .

HY-RS09212

NET1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NET1 Human Pre-designed siRNA Set A contains three designed siRNAs for NET1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NET1 Human Pre-designed siRNA Set A NET1 Human Pre-designed siRNA Set A

HY-103217

Talopram hydrochloride	Monoamine Transporter	Neurological Disease
Talopram hydrochloride is a selective inhibitor for norepinephrine transporter (NET), that inhibits 63% human NET at 100 nM .

HY-110223

Atomoxetine-d3 hydrochloride	Adrenergic Receptor	Neurological Disease
Atomoxetine-d3 hydrochloride is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-17385S

Atomoxetine-d5 hydrochloride Tomoxetine-d5 hydrochloride; LY 139603-d5 ; (R)-Tomoxetine-d5 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride (Rac)-Tomoxetine D7 hydrochloride; (Rac)-LY 139603 D7	Serotonin Transporter Sodium Channel Isotope-Labeled Compounds	Neurological Disease
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-129934S

Latanoprost ethyl amide-d4 Lat-NET-d₄	Isotope-Labeled Compounds Prostaglandin Receptor	Endocrinology
Latanoprost ethyl amide-d₄ (Lat-NEt-d₄) is deuterium labeled Latanoprost ethyl amide. Latanoprost ethyl amide (Lat-NEt) is a latanoprost analog in which the C-1 carboxyl group has been modified to an N-ethyl amide. Prostaglandin esters have been shown to have ocular hypotensive activity.1 Prostaglandin N-ethyl amides were recently introduced as alternative prostaglandin ocular hypotensive prodrugs. Although it has been claimed that prostaglandin ethyl amides are not converted to the free acids in vivo, studies in our laboratories have shown that bovine and human corneal tissue converts the N-ethyl amides of various prostaglandins to the free acids with a conversion rate of about 2.5 μg/g corneal tissue/hr. Lat-NEt would be expected to show the typical intraocular effects of Latanoprost free acid, but with the much slower hydrolysis pharmacokinetics of the prostaglandin N-amides .

HY-129934

Latanoprost ethyl amide Lat-NET	Prostaglandin Receptor	Endocrinology
Latanoprost ethyl amide (Lat-NEt) is a latanoprost analog in which the C-1 carboxyl group has been modified to an N-ethyl amide. Prostaglandin esters have been shown to have ocular hypotensive activity.1 Prostaglandin N-ethyl amides were recently introduced as alternative prostaglandin ocular hypotensive prodrugs. Although it has been claimed that prostaglandin ethyl amides are not converted to the free acids in vivo, studies in our laboratories have shown that bovine and human corneal tissue converts the N-ethyl amides of various prostaglandins to the free acids with a conversion rate of about 2.5 μg/g corneal tissue/hr. Lat-NEt would be expected to show the typical intraocular effects of Latanoprost free acid, but with the much slower hydrolysis pharmacokinetics of the prostaglandin N-amides.

HY-103293B

Lys-Bradykinin tetraacetate Kallidin (380-389) (human, porcine, bovine) tetraacetate	Bradykinin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Lys-Bradykinin (Kallidin (380-389) (human, porcine, bovine)) tetraacetate, a kind of kallidin and bradykinin receptor ligand, can be generated by kininogen protein through enzymatic cleavage by the protease kallikrein. Lys-Bradykinin tetraacetate, also a vasodilator, can widen blood vessels and increase blood flow. ys-Bradykinin stimulates net Na+ influx, and also the DNA synthesis. Lys-Bradykinin tetraacetate involves in vascular regulation, inflammation and pain sensation .

HY-14794AS

Levomilnacipran-d10 hydrochloride (1S,2R)-Milnacipran-d10 hydrochloride; F2695-d10 hydrochloride	Isotope-Labeled Compounds Serotonin Transporter Trk Receptor PI3K mTOR P-glycoprotein Akt	Neurological Disease Inflammation/Immunology
Levomilnacipran-d₁₀ ((1S,2R)-Milnacipran-d₁₀) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .

HY-B0168BS

Levomilnacipran-d5 hydrochloride (1S,2R)-Milnacipran-d5 hydrochloride; F-2695-d5 hydrochloride	Isotope-Labeled Compounds Serotonin Transporter Trk Receptor PI3K Akt mTOR P-glycoprotein	Neurological Disease Inflammation/Immunology
Levomilnacipran-d5 ((1S,2R)-Milnacipran-d5) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .

HY-182244

SERT/NET-IN-1	Serotonin Transporter 5-HT Receptor	Endocrinology
SERT/NET-IN-1 is a blood-brain barrier-permeable SERT and *NET* inhibitor, with an IC₅₀ of 11.2 nM against human SERT and an IC₅₀ of 32.0 nM against human *NET. SERT/NET-IN-1 blocks 5-HT reuptake to enhance serotonergic signaling. SERT/NET-IN-1 also blocks norepinephrine reuptake to enhance central noradrenergic transmission and inhibits the ejaculatory reflex. SERT/NET-IN-1 prolongs ejaculatory latency, reduces ejaculation frequency and preserves sexual function. SERT/NET-IN-1 exhibits cross-species microsomal metabolic stability, shows acceptable oral brain exposure in rats, and has favorable safety profiles. SERT/NET*-IN-1 can be used in studies related to premature ejaculation .

HY-W680886

6-APDB	Monoamine Transporter Serotonin Transporter Dopamine Transporter 5-HT Receptor	Neurological Disease
6-APDB is a class of monoamine neurotransmitter releaser and Monoamine Transporter modulator that exerts selective effects on human monoamine transporters and acts as a partial agonist at 5-HT₂ family receptors. For *NET, 6-APDB has an IC₅₀* of 0.56 μM and a K_i of 18 μM; for SERT, it has an IC₅₀ of 2.3 μM and a K_i of 23 μM; for DAT, it has an IC₅₀ of 33 μM and a K_i of >30 μM, and affinity for rat and mouse TAAR1, with K_i values of 1.0 μM and 0.21 μM, respectively. 6-APDB inhibits norepinephrine and 5-HT reuptake, mediates the release of three types of monoamine neurotransmitters, shows a dose-dependent biphasic locomotor effect in mice, and fully substitutes the discriminative stimulus effect of MDMA. 6-APDB shows no significant cytotoxicity at high concentrations, and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behavioral effects associated with intermittent abuse .

HY-P11657

GN-2 peptoid	Bacterial	Infection
GN-2 peptoid is a 9-mer cationic amphipathic peptoid and bactericidal agent with an overall net charge of +4, broad-spectrum antimicrobial activity, and low hemolytic and cytotoxic activity against mammalian cells. GN-2 peptoid exerts bactericidal action against Escherichia coli in a concentration-dependent manner. GN-2 peptoid exhibits antimicrobial activity against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli, Pseudomonas aeruginosa strains. GN-2 peptoid shows low toxicity against human red blood cells and HeLa cells. GN-2 peptoid maintains antimicrobial activity in the presence of 50% human blood plasma. GN-2 peptoid can be used for the research of bacterial infections .

HY-181828

SePP	iGluR Dopamine Receptor	Neurological Disease
SePP is a blood-brain barrier-permeable NMDAR antagonist and dopamine/norepinephrine reuptake inhibitor, with a K_i of 28.7 nM for rat NMDAR. SePP exerts anticonvulsant effects. SePP can be used in research related to fragile X syndrome .

Cat. No.	Product Name

HY-L906

Norepinephrine Transporter (NET) Compound Library	647 compounds
On May 15, 2024, "Dimerization and antidepressant recognition at noradrenaline transporter" was published online by Nature. The research findings were an effort from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This study unraveled the important neural system target - the noradrenaline transporter (NET), obtaining the binding modes of human NET homodimers with the natural substrate norepinephrine (NE) and six selective antidepressants. It laid an important theoretical foundation for understanding the physiological regulation mechanisms of NET and other monoamine transporters. The Norepinephrine Transporter (NET) Compound Library is obtained by computer-aided virtual screening based on the HY-L901 compound library . The specific screening process includes molecular docking screening, key pharmacophore screening, and CNS-MPO screening, which can be used for new drug discovery targeting the noradrenaline transporter.

Norepinephrine Transporter (NET) Compound Library

647 compounds

On May 15, 2024, "Dimerization and antidepressant recognition at noradrenaline transporter" was published online by Nature. The research findings were an effort from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This study unraveled the important neural system target - the noradrenaline transporter (NET), obtaining the binding modes of human NET homodimers with the natural substrate norepinephrine (NE) and six selective antidepressants. It laid an important theoretical foundation for understanding the physiological regulation mechanisms of NET and other monoamine transporters.

The Norepinephrine Transporter (NET) Compound Library is obtained by computer-aided virtual screening based on the HY-L901 compound library . The specific screening process includes molecular docking screening, key pharmacophore screening, and CNS-MPO screening, which can be used for new drug discovery targeting the noradrenaline transporter.

HY-L058

Glycolysis Compound Library	1,258 compounds
Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation. Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications. MCE provides a unique collection of 1,258 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Glycolysis Compound Library

1,258 compounds

Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation.

Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.

MCE provides a unique collection of 1,258 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-103293B

Lys-Bradykinin tetraacetate Kallidin (380-389) (human, porcine, bovine) tetraacetate	Bradykinin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Lys-Bradykinin (Kallidin (380-389) (human, porcine, bovine)) tetraacetate, a kind of kallidin and bradykinin receptor ligand, can be generated by kininogen protein through enzymatic cleavage by the protease kallikrein. Lys-Bradykinin tetraacetate, also a vasodilator, can widen blood vessels and increase blood flow. ys-Bradykinin stimulates net Na+ influx, and also the DNA synthesis. Lys-Bradykinin tetraacetate involves in vascular regulation, inflammation and pain sensation .

HY-P11657

GN-2 peptoid	Bacterial	Infection
GN-2 peptoid is a 9-mer cationic amphipathic peptoid and bactericidal agent with an overall net charge of +4, broad-spectrum antimicrobial activity, and low hemolytic and cytotoxic activity against mammalian cells. GN-2 peptoid exerts bactericidal action against Escherichia coli in a concentration-dependent manner. GN-2 peptoid exhibits antimicrobial activity against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli, Pseudomonas aeruginosa strains. GN-2 peptoid shows low toxicity against human red blood cells and HeLa cells. GN-2 peptoid maintains antimicrobial activity in the presence of 50% human blood plasma. GN-2 peptoid can be used for the research of bacterial infections .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99444

Astegolimab 2 Publications Verification MSTT 1041A; RG 6149	Interleukin Related MDM-2/p53 NF-κB	Cardiovascular Disease Inflammation/Immunology
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .

Species:	Human (9)
Tag:	SUMO (1) His (5) Tag Free (1) Myc (1) GST (1) Fc (3)
Source:	HEK293 (5) Sf9 insect cells (1) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P77260

	*TSPAN1 Protein, Human* (HEK293, His)** Tetraspanin-1; Tspan-1; Tetraspan NET-1; Tetraspanin TM4-C	Human	HEK293
	TSPAN1 Protein is a member of the tetraspanin (TSPAN/TM4SF) family of proteins whose important feature is their ability to aggregate with one another or various other transmembrane receptors, to become TSPAN-enriched microdomains (TEMs). TSPAN1 functions as an oncoprotein in many cancer types, especially digestive malignancies such as hepatocellular carcinoma (HCC), pancreatic, gastric, colorectal, and esophageal cancers. TSPAN1 is a novel positive regulator of macroautophagy/autophagy characterized by decreased LC3-II and SQSTM1/p62 expressions, inhibited puncta formation of GFP-LC3 and autophagic vacuoles. TSPAN1 Protein, Human (HEK293, His) is the recombinant human-derived TSPAN1 protein, expressed by HEK293 , with N-His labeled tag.

HY-P77261

	*TSPAN1 Protein, Human* (HEK293, rFc)** Tetraspanin-1; Tspan-1; Tetraspan NET-1; Tetraspanin TM4-C	Human	HEK293
	TSPAN1 Protein is a member of the tetraspanin (TSPAN/TM4SF) family of proteins whose important feature is their ability to aggregate with one another or various other transmembrane receptors, to become TSPAN-enriched microdomains (TEMs). TSPAN1 functions as an oncoprotein in many cancer types, especially digestive malignancies such as hepatocellular carcinoma (HCC), pancreatic, gastric, colorectal, and esophageal cancers. TSPAN1 is a novel positive regulator of macroautophagy/autophagy characterized by decreased LC3-II and SQSTM1/p62 expressions, inhibited puncta formation of GFP-LC3 and autophagic vacuoles. TSPAN1 Protein, Human (HEK293, rFc) is the recombinant human-derived TSPAN1 protein, expressed by HEK293 , with N-rFc labeled tag.

HY-P77262

	*TSPAN1 Protein, Human* (HEK293, Fc)** Tetraspanin-1; Tspan-1; Tetraspan NET-1; Tetraspanin TM4-C	Human	HEK293
	TSPAN1 Protein is a member of the tetraspanin (TSPAN/TM4SF) family of proteins whose important feature is their ability to aggregate with one another or various other transmembrane receptors, to become TSPAN-enriched microdomains (TEMs). TSPAN1 functions as an oncoprotein in many cancer types, especially digestive malignancies such as hepatocellular carcinoma (HCC), pancreatic, gastric, colorectal, and esophageal cancers. TSPAN1 is a novel positive regulator of macroautophagy/autophagy characterized by decreased LC3-II and SQSTM1/p62 expressions, inhibited puncta formation of GFP-LC3 and autophagic vacuoles. TSPAN1 Protein, Human (HEK293, Fc) is the recombinant human-derived TSPAN1 protein, expressed by HEK293 , with N-mFc labeled tag.

HY-P72998

	*EphB1 Protein, Human* (HEK293, His)** Ephrin type-B receptor 1; ELK; EK6; NET; EPHB1; EPHT2; HEK6	Human	HEK293
	The EphB1 protein is a receptor tyrosine kinase that promiscuously binds to the transmembrane ephrin-B ligand of adjacent cells, initiating bidirectional signaling. The forward signal originates from the receptor and the reverse signal originates from the ephrin ligand. EphB1 Protein, Human (HEK293, His) is the recombinant human-derived EphB1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P72997

	*EphB1 Protein, Human* (Active, sf9, His-GST)** Ephrin type-B receptor 1; ELK; EK6; NET; EPHB1; EPHT2; HEK6	Human	Sf9 insect cells
	The EphB1 protein is a receptor tyrosine kinase that promiscuously binds to the transmembrane ephrin-B ligand of adjacent cells, initiating bidirectional signaling. The forward signal originates from the receptor and the reverse signal originates from the ephrin ligand. EphB1 Protein, Human (sf9, His-GST) is the recombinant human-derived EphB1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P70381

	*EphB1 Protein, Human* (HEK293, Fc)** rHuEphrin type-B receptor 1/EphB1, Fc; Ephrin Type-B Receptor 1; ELK; EPH Tyrosine Kinase 2; EPH-Like Kinase 6; EK6; hEK6; Neuronally-Expressed EPH; Related Tyrosine Kinase; NET; Tyrosine-Protein Kinase Receptor EPH-2; EPHB1; ELK; EPHT2; HEK6	Human	HEK293
	The EphB1 protein is a receptor tyrosine kinase that promiscuously binds to the transmembrane ephrin-B ligand of adjacent cells, initiating bidirectional signaling. The forward signal originates from the receptor and the reverse signal originates from the ephrin ligand. EphB1 Protein, Human (HEK293, Fc) is the recombinant human-derived EphB1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P702709

	EphB1 Protein, Human EPHB1; EPH receptor B1; EphB1 , EPHT2; ephrin type-B receptor 1; Hek6; EK6; EPH-like kinase 6; eph tyrosine kinase 2; soluble EPHB1 variant 1; tyrosine-protein kinase receptor EPH-2; neuronally-expressed EPH-related tyrosine kinase; ELK; NET; EPHT2; FLJ37986	Human	E. coli
	The EphB1 protein is a receptor tyrosine kinase that promiscuously binds to the transmembrane ephrin-B ligand of adjacent cells, initiating bidirectional signaling. The forward signal originates from the receptor and the reverse signal originates from the ephrin ligand. EphB1 Protein, Human is the recombinant human-derived EphB1, expressed by E. coli, with tag-free. The total length of EphB1 Protein, Human is 295 a.a..

HY-P705819

	*EphB1 Protein, Human* (Active, sf9, His)** rHuEphrin Type-B Receptor 1/Ephb1, His; Ephrin Type-B Receptor 1; ELK; EPH Tyrosine Kinase 2; EPH-Like Kinase 6; EK6; hEK6; Neuronally-Expressed EPH; Related Tyrosine Kinase; NET; Tyrosine-Protein Kinase Receptor EPH-2; EPHB1; ELK; EPHT2; HEK6	Human	E. coli

HY-P71585

	*KDM3B Protein, Human* (Myc, His-SUMO)** 5qNCA; C5orf7; JHDM2B; JmjC domain containing histone demethylation protein 2B; JmjC domain-containing histone demethylation protein 2B; jmjd1b; Jumonji domain containing 1B; Jumonji domain containing protein 1B; Jumonji domain-containing protein 1B; KDM3B; KDM3B_human; KIAA1082; Lysine (K) specific demethylase 3B ; Lysine-specific demethylase 3B; NET22; Nuclear protein 5qNCA	Human	E. coli
	KDM3B protein is a histone demethylase that mainly targets "Lys-9" of histone H3, catalyzes demethylation and produces formaldehyde and succinic acid by-products. In addition to histone modifications, KDM3B has been implicated in tumor suppressor activity, indicating its importance in cellular processes, gene expression regulation, and epigenetic modifications. KDM3B Protein, Human (Myc, His-SUMO) is the recombinant human-derived KDM3B protein, expressed by E. coli , with C-Myc, N-SUMO, N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17385S

Atomoxetine-d5 hydrochloride
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-129934S

Latanoprost ethyl amide-d4
Latanoprost ethyl amide-d₄ (Lat-NEt-d₄) is deuterium labeled Latanoprost ethyl amide. Latanoprost ethyl amide (Lat-NEt) is a latanoprost analog in which the C-1 carboxyl group has been modified to an N-ethyl amide. Prostaglandin esters have been shown to have ocular hypotensive activity.1 Prostaglandin N-ethyl amides were recently introduced as alternative prostaglandin ocular hypotensive prodrugs. Although it has been claimed that prostaglandin ethyl amides are not converted to the free acids in vivo, studies in our laboratories have shown that bovine and human corneal tissue converts the N-ethyl amides of various prostaglandins to the free acids with a conversion rate of about 2.5 μg/g corneal tissue/hr. Lat-NEt would be expected to show the typical intraocular effects of Latanoprost free acid, but with the much slower hydrolysis pharmacokinetics of the prostaglandin N-amides .

Latanoprost ethyl amide-d4

Latanoprost ethyl amide-d₄ (Lat-NEt-d₄) is deuterium labeled Latanoprost ethyl amide. Latanoprost ethyl amide (Lat-NEt) is a latanoprost analog in which the C-1 carboxyl group has been modified to an N-ethyl amide. Prostaglandin esters have been shown to have ocular hypotensive activity.1 Prostaglandin N-ethyl amides were recently introduced as alternative prostaglandin ocular hypotensive prodrugs. Although it has been claimed that prostaglandin ethyl amides are not converted to the free acids in vivo, studies in our laboratories have shown that bovine and human corneal tissue converts the N-ethyl amides of various prostaglandins to the free acids with a conversion rate of about 2.5 μg/g corneal tissue/hr. Lat-NEt would be expected to show the typical intraocular effects of Latanoprost free acid, but with the much slower hydrolysis pharmacokinetics of the prostaglandin N-amides .

HY-14794AS

Levomilnacipran-d10 hydrochloride
Levomilnacipran-d₁₀ ((1S,2R)-Milnacipran-d₁₀) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .

Levomilnacipran-d10 hydrochloride

Levomilnacipran-d₁₀ ((1S,2R)-Milnacipran-d₁₀) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .

HY-B0168BS

Levomilnacipran-d5 hydrochloride

Levomilnacipran-d5 ((1S,2R)-Milnacipran-d5) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .

Host:	Rabbit (2)
Reactivity:	Human (2) Mouse (2)
Application:	IHC-P (2) ICC/IF (2) IF-Tissue (1) IHC-F (1) WB (2) FC (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86931

	KDM3B Antibody (YA6624) 5qNCA antibody; C5orf7 antibody; JHDM2B antibody; JmjC domain containing histone demethylation protein 2B antibody; JmjC domain-containing histone demethylation protein 2B antibody; jmjd1b antibody; Jumonji domain containing 1B antibody; Jumonji domain containing protein 1B antibody; Jumonji domain-containing protein 1B antibody; KDM3B antibody; 5qNCA antibody; C5orf7 antibody; JHDM2B antibody; JmjC domain containing histone demethylation protein 2B antibody; JmjC domain-containing histone demethylation protein 2B antibody; jmjd1b antibody; Jumonji domain containing 1B antibody; Jumonji domain containing protein 1B antibody; Jumonji domain-containing protein 1B antibody; KDM3B antibody; KDM3B_human antibody; KIAA1082 antibody; Lysine (K) specific demethylase 3B antibody; Lysine-specific demethylase 3B antibody; NET22 antibody; Nuclear protein 5qNCA antibody;	WB, IHC-P, ICC/IF, FC	Human, Mouse
	KDM3B Antibody (YA6624) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to KDM3B.

HY-P86872

	Erlin-2 Antibody (YA6565) C8orf2 antibody; Chromosome 8 open reading frame 2 antibody; Endoplasmic reticulum lipid raft associated protein 2 antibody; Endoplasmic reticulum lipid raft-associated protein 2 antibody; ER lipid raft associated 2 antibody; ERLIN 2 antibody; Erlin-2 antibody; ERLIN2 antibody; ERLN2_human antibody; HGNC:1356 antibody; C8orf2 antibody; Chromosome 8 open reading frame 2 antibody; Endoplasmic reticulum lipid raft associated protein 2 antibody; Endoplasmic reticulum lipid raft-associated protein 2 antibody; ER lipid raft associated 2 antibody; ERLIN 2 antibody; Erlin-2 antibody; ERLIN2 antibody; ERLN2_human antibody; HGNC:1356 antibody; MGC87072 antibody; NET32 antibody; SPFH 2 antibody; SPFH domain containing protein 2 antibody; SPFH domain family member 2 antibody; SPFH domain-containing protein 2 antibody; SPFH2 antibody; SPG18 antibody; Stomatin prohibitin flotillin HflC/K domain containing protein 2 antibody; Stomatin-prohibitin-flotillin-HflC/K domain-containing protein 2 antibody;	WB, IHC-P, IHC-F, ICC/IF, FC, IF-Tissue	Human, Mouse
	Erlin-2 Antibody (YA6565) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Erlin-2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS09212

NET1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
NET1 Human Pre-designed siRNA Set A contains three designed siRNAs for NET1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides